A self-experiment in human fertility data offers the first documented case study of psilocybin’s transient – and potentially restorative – effect on sperm quality.
The Spore Report covers psychedelics, mycology, neuroplasticity, and regenerative health. Subscribe to The Spore Report
Bryan Johnson measures everything. His sleep, his inflammation markers, his biological age, his glucose curves, even his night time erection quality (I know, too much information). So it was particularly interested when he recently took 5 grams of psilocybin mushrooms.
Among many other interesting effects, his fertility markers collapsed in the weeks after the session. Sounds bad, but 90 days later, those same markers came back at the best numbers he had ever recorded.
The crash
Johnson’s post-psilocybin sperm panel made for uncomfortable reading. Total motile count dropped 69%, from a previous best of 330 million to just 101 million. Motility fell from 55% to 29%. Morphology halved. Basically every marker moved in the wrong direction.
The mechanism at play here is this: Sperm cells carry 5-HT2A receptors, the same serotonin receptors that psilocybin activates in the brain. When psilocybin triggers those receptors on sperm, the cells begin swimming in frantic, erratic patterns far earlier than they usually would. They soon burn out, and a fertility test reads them as non-motile or abnormal.
At the same time, psilocybin drives up cortisol, ACTH, and prolactin in the hours following a session. Elevated prolactin signals the testes to slow or pause production.
The rebound
Human sperm takes roughly 9 to 11 weeks to develop from stem cell to mature gamete. So three months after the crash, Johnson retested. Every single number came back better than his previous personal best.
| Parameter | Post-psilocybin | 90 days later | Previous best |
|---|---|---|---|
| Total motile count (M) | 101 | 411 | 330 |
| Motility (%) | 29% | 64% | 55% |
| Morphology (%) | 5% | 12% | 10% |
| Concentration (M/mL) | 125 | 212 | 162 |
| Count (M) | 349 | 642 | 600 |
For context: the WHO considers a motile count above 42 million normal. Johnson’s rebound figure of 411 million is nearly 10 times that threshold. A normal concentration sits around 16 million/mL. His came back at 212 million/mL, placing him in the top 1% of all males tested.
As Johnson put it: “It appears that the factory shut down for one cycle and then rebuilt everything from scratch.”
Did psilocybin cause the improvement?
Whether the rebound represents a psilocybin-triggered regenerative reset, a pre-existing upward trend, or some combination of both is not known. He also underwent a 5-MeO-DMT session in the same period, though that compound clears the body in one to two hours, which is too fast to sustain the receptor activation that appears to drive the initial disruption.
Confounders exist. Extensive travel, a trip to China, and three weeks of disrupted sleep in December 2025 likely contributed to the initial decline. Neither alone accounts for a 69% drop in motile count, but the interaction of multiple stressors alongside the acute pharmacology of psilocybin remains plausible.
This isn’t just a fertility story
The sperm data is striking, but it sits within a much larger self-experiment that Johnson has been running. Across two documented psilocybin sessions, the metabolic and systemic effects he measured go well beyond reproductive health.
His hsCRP, a marker of systemic inflammation, dropped over 35% after his second session, falling below the detection limit of the assay. Five days post-trip, cortisol dropped 42% and DHEA-S fell 45%. While cortisol spikes acutely during the session itself, his body subsequently shifted into sustained parasympathetic dominance – a state he described as “sustained joy and relaxation” that persisted for days.
His glucose regulation improved in ways that outlasted the drug’s clearance from his system. Brain imaging using Kernel Flow sensors documented the now-familiar suppression of the Default Mode Network and dimming of the prefrontal cortex at peak, followed by a prolonged afterglow of sharpened senses and heightened cognitive flexibility.
This broader picture now has mechanistic support from the research literature. A 2025 study from Emory University and Baylor College of Medicine, published in npj Aging, provided the first experimental evidence that psilocybin acts on cellular aging directly, not just through the brain.
Psilocin extended cellular lifespan by 29 to 57% in isolated fibroblasts. It preserved telomere length, reduced oxidative stress, improved DNA stability, and increased SIRT1, a master regulator of cellular metabolism and longevity that is also elevated during caloric restriction.
Critically, these effects were observed in cells with no connection to a nervous system whatsoever. The compound was acting directly on fundamental aging processes at the cellular level.
Why the sperm story fits the larger model
The 5-HT2A receptor that psilocybin activates isn’t just in the brain. It is expressed in fibroblasts, heart cells, immune cells, endothelial cells, pancreatic cells, and throughout the liver and metabolic organs. The sperm crash and rebound is, in a sense, the reproductive system offering an unusually legible readout of what psilocybin does systemically: a temporary disruption of normal function followed by what appears to be a higher-quality reconstitution.
If the Emory findings hold, then what Johnson observed in his sperm panel might be one visible signal of a much deeper regenerative process happening simultaneously across every tissue in his body.
The researchers describe psilocybin as a potential “disruptive pharmacotherapy” and geroprotective agent. That framing is starting to look less like speculation.
What this means for the field
To our knowledge, Johnson’s fertility data represents the first documented case of psilocybin’s transient effect on human sperm quality. It aligns with existing receptor biology and with what we know about prolactin-mediated suppression of spermatogenesis. But a single data point is not a mechanism, and a single subject is not a study.
What it does is open a door. The question of whether a psilocybin-induced spermatogenic pause followed by full regeneration might, under the right conditions, produce a superior cohort is interesting. But it would require prospective study, controlled baselines, and replication across multiple individuals.
More broadly, the convergence of his self-experiment data with the Emory cellular aging research points toward a reframing that has been building for a few years. Psychedelics are not consciousness drugs with interesting side effects. They are systemic metabolic agents that happen to produce consciousness-altering experiences through their effects on the brain. The cellular and mitochondrial effects are not secondary. They may be primary.
We are at the very beginning of understanding what that means.
The Spore Report covers psychedelics, mycology, neuroplasticity, and regenerative health. Subscribe to The Spore Report
Good morning sir I need p